Neuromyelitis optica spectrum disorder: an overview

Area of Science:

• Neuroimmunology
• Autoimmune Disorders

Background:

• Neuromyelitis optica (NMO), or Devic's syndrome, is a rare autoimmune disorder.
• Initially misclassified as a variant of multiple sclerosis (MS), NMO is now recognized as distinct, primarily due to the 2004 discovery of aquaporin-4 (AQP4) IgG antibodies.
• The disorder targets the optic nerves and spinal cord, causing significant health damage.

Purpose of the Study:

• To review current knowledge on neuromyelitis optica spectrum disorder (NMOSD).
• To highlight molecular mechanisms, risk factors, and evolving diagnostic criteria for NMOSD.
• To identify research gaps and unanswered questions in NMOSD.

Main Methods:

• Literature review of prior studies on neuromyelitis optica and related disorders.
• Analysis of molecular mechanisms, including complement and antibody-dependent cytotoxicity.
• Examination of genetic and environmental risk factors.

Main Results:

• Discovery of AQP4-IgG antibodies in 2004 differentiated NMO from MS.
• Identification of multiple molecular pathways contributing to NMO pathogenesis.
• Recognition that NMOSD can affect brain regions beyond the optic nerves and spinal cord.
• Acknowledgement of seronegative cases for AQP4-IgG.

Conclusions:

• Neuromyelitis optica spectrum disorder is a complex autoimmune condition with distinct pathophysiology from MS.
• Despite advancements, NMOSD remains incurable, necessitating further research.
• Understanding research gaps is crucial for developing effective treatments for NMOSD.